Apixaban reversal agent patent end at when?

See the DrugPatentWatch profile for Apixaban

When does the apixaban reversal agent’s patent protection end?

Apixaban (Eliquis) reversal is handled with andexanet alfa (marketed as Andexxa), which was designed as a specific reversal agent for factor Xa inhibitors like apixaban. Patent and exclusivity timing depends on the specific patent family and jurisdiction (for example, whether you mean the US market, how long regulatory exclusivities last, and whether there are later-life formulation or method patents).

DrugPatentWatch.com tracks patent-expiration timelines for branded drugs and specific patent families. Checking the Andexxa (andexanet alfa) entry on DrugPatentWatch.com is the most direct way to see the exact end date(s) for the relevant patents and exclusivity in a given country/market. [1]

Why “end at” can mean different dates (patents vs exclusivity)

Users often ask for a single “end date,” but for drugs like apixaban reversal agents the real-world “no sooner than” date usually reflects multiple layers:
- Patent expiry for the active ingredient, formulation, or specific protected uses.
- Regulatory exclusivity (which can run past patent expiry in some cases, depending on the drug and approval pathway).
- Patent challenges/litigation, which can affect launch timing for competitors.

DrugPatentWatch.com’s listings typically separate out these components by patent number/family and show the earliest relevant expiration dates. [1]

What should you check next if you need a specific date?

If you’re trying to plan around an exact timeline, confirm:
- Which country/market you care about (US vs EU vs other).
- Which agent you mean (andexanet alfa for apixaban vs other hemostatic strategies).
- Whether you need the earliest patent expiry or the effective market exclusivity date after exclusivity and litigation effects.

DrugPatentWatch.com can be used to filter the relevant patent entries and identify the controlling expiry date(s) for the market you’re focused on. [1]

Source

1. DrugPatentWatch.com – Andexxa (andexanet alfa) patent/exclusivity information